Eculizumab

In the US, Eculizumab (eculizumab systemic) is a member of the drug class selective immunosuppressants and is used to treat Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.

US matches:

• Eculizumab


• Eculizumab Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA25

CAS registry number (Chemical Abstracts Service)

0219685-50-4

Therapeutic Categories

Selective immunosuppressant

Monoclonal antibody

Chemical Name

Immunoglobulin, anit-(human complement C5 α-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G1.1 light chain, dimer (WHO)

Foreign Names

• Eculizumabum (Latin)
• Eculizumab (German)
• Eculizumab (French)
• Eculizumab (Spanish)

Generic Names

• Eculizumab (OS: USAN)
• AX-451 (IS)
• h5G1.1 (IS)
• h5G1.1VHC+h51.1VLC (IS)

Brand Names

• Soliris
  Alexicon, United Kingdom; Alexion, Austria; Alexion, Canada; Alexion, Switzerland; Alexion, Germany; Alexion, Spain; Alexion, France; Alexion, Luxembourg; Alexion, Netherlands; Alexion, United States; Alexion Pharma France, Denmark



• SOLIRIS
  Alexion, Sweden

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.